Danaher Corporation $DHR Shares Newly Bought by Summit Financial Wealth Advisors LLC

Summit Financial Wealth Advisors LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,201 shares of the conglomerate’s stock, valued at approximately $1,374,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. Marquette Asset Management LLC increased its stake in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Main Street Group LTD bought a new position in shares of Danaher during the 1st quarter worth approximately $25,000. Field & Main Bank bought a new position in shares of Danaher during the 2nd quarter worth approximately $29,000. Finally, Evolution Wealth Management Inc. boosted its stake in shares of Danaher by 208.0% in the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after buying an additional 104 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR stock opened at $231.52 on Friday. The firm has a market cap of $162.76 billion, a price-to-earnings ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm’s 50-day simple moving average is $213.55 and its two-hundred day simple moving average is $195.74.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period in the previous year, the company earned $0.77 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is 28.42%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DHR shares. The Goldman Sachs Group upped their target price on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a report on Monday, September 21st. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. Wells Fargo & Company dropped their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Finally, Evercore reissued an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $235.41.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.